Where does Rempex Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Rempex Pharmaceuticals, Inc. ranks #13,652 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Rempex Pharmaceuticals, Inc. hold?

Rempex Pharmaceuticals, Inc. holds 22 US utility patents granted between 2015 and 2020, spanning 8 technology areas.

What is Rempex Pharmaceuticals, Inc.'s Innovation Score?

Rempex Pharmaceuticals, Inc. has an Innovation Score of 35.8 out of 100 (top 48% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Rempex Pharmaceuticals, Inc. focus on?

Rempex Pharmaceuticals, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 19 patents, ranking #1,197 of 7,163 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Rempex Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Rempex Pharmaceuticals, Inc.'s recent grant velocity is -84% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Rempex Pharmaceuticals, Inc.'s patents?

Rempex Pharmaceuticals, Inc.'s patents average 28.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Rempex Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Rempex Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 22 granted patents across 8 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Rempex ranks #13,652 of 49,997 tracked US assignees by granted-patent volume, with 22 patents across 8 technology areas.

#13,652
of 49,997 US assignees by volume: Top 48%
by Innovation Score (35.8/100): 28.6
avg claims per patent: -84%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13652 · US Corporation #13,652 · 22 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 22 grants
MID-PACK #13,652/49,997
PHOTO-FINISH Rainlight Studio
CPC-NARROW A61K · 8 areas
INNOV-THIN 35.8/100
CLAIMS-DENSE 28.6 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -84% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Rainlight Studio LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Rempex’s 35.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.8 pts (30%) Velocity 0.0 pts (0%) Breadth 10.0 pts (28%) Claim depth 15.0 pts (42%)

Qualcomm Incorporated · highest

85
Rempex Pharmaceuticals · this assignee

36
3D Lighting… · lowest

7

What this shows Rempex's Innovation Score is 35.8/100 (top 48% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Rempex?

Each dot is one of Rempex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Rempex’s own 28.6 claims/patent is ABOVE the 12.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Rempex vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Rempex's grants concentrate

Rempex Pharmaceuticals, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 86.4% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2015 (6 grants) versus a trough of 2 in 2018. By volume, Rempex sits between Rainlight Studio LLC and ROM Acquisition Corporation.

Rainlight Studio

22
Reckitt & Colman…

22
Recover Energy Se…

22
Reliance JIO Info…

22
RGF Environmental…

22
RIC Investments

22
ROI Optoelectroni…

22
ROM Acquisition

22
Rempex Pharmaceut… ◀

22

What this shows Rempex holds 22 patents at rank #13,646, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Rempex

By rank, the assignees closest to #13,646 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Rempex's primary technology class.

Rempex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 48% higher than 52% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Rempex Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	27.3%
2016	3	13.6%
2017	4	18.2%
2018	2	9.1%
2019	4	18.2%
2020	3	13.6%

Which technologies does Rempex Pharmaceuticals, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 19

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 18

Y02A - Technologies FOR Adaptation TO Climate Change 15

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

C07K - Peptides 1

C07D - Heterocyclic Compounds 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Rempex Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Rempex Pharmaceuticals, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 86.4% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #13,652 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Rempex Pharmaceuticals, Inc. against Rainlight Studio LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.